About: The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses
Creator	Dietrich, Ursula Eichler, Jutta Büning, Hildegard Debré, Patrice Ringel, Oliver Vieillard, Vincent
Source	Medline; PMC
abstract	Although effective antibody-based vaccines have been developed against multiple viruses, such approaches have so far failed for the human immunodeficiency virus type 1 (HIV-1). Despite the success of anti-retroviral therapy (ART) that has turned HIV-1 infection into a chronic disease and has reduced the number of new infections worldwide, a vaccine against HIV-1 is still urgently needed. We discuss here the major reasons for the failure of “classical” vaccine approaches, which are mostly due to the biological properties of the virus itself. HIV-1 has developed multiple mechanisms of immune escape, which also account for vaccine failure. So far, no vaccine candidate has been able to induce broadly neutralizing antibodies (bnAbs) against primary patient viruses from different clades. However, such antibodies were identified in a subset of patients during chronic infection and were shown to protect from infection in animal models and to reduce viremia in first clinical trials. Their detailed characterization has guided structure-based reverse vaccinology approaches to design better HIV-1 envelope (Env) immunogens. Furthermore, conserved Env epitopes have been identified, which are promising candidates in view of clinical applications. Together with new vector-based technologies, considerable progress has been achieved in recent years towards the development of an effective antibody-based HIV-1 vaccine.
has issue date	2018-04-15(xsd:dateTime)
bibo:doi	10.3390/v10040197
bibo:pmid	29662026
has license	cc-by
sha1sum (hex)	b0e519e2224e5ee8dd2303ed3f347e049cb599a2
schema:url	https://doi.org/10.3390/v10040197
resource representing a document's title	The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses
has PubMed Central identifier	PMC5923491
has PubMed identifier	29662026
schema:publication	Viruses
resource representing a document's body	covid:b0e519e2224e5ee8dd2303ed3f347e049cb599a2#body_text
is schema:about of	named entity 'HIV-1' named entity 'progress' named entity 'HIV-1' named entity 'Vaccine' named entity 'APPLICATIONS' named entity 'DIFFERENT' named entity 'HIV-1' named entity 'HAVE' named entity 'STRUCTURE' named entity 'CONSIDERABLE' named entity 'NEEDED' named entity 'THEIR' named entity 'FAILURE' named entity 'CONSERVED' named entity 'RECENT' named entity 'REASONS' named entity 'ANTIBODIES' named entity 'HIV-1' named entity 'TECHNOLOGIES' named entity 'MAJOR' named entity 'REDUCED' named entity 'DEVELOPMENT' named entity 'IMMUNE' named entity 'EFFECTIVE' named entity 'PRIMARY' named entity 'PROGRESS' named entity 'CHRONIC INFECTION' named entity 'PATIENTS' named entity 'IDENTIFIED' named entity 'WORLDWIDE' named entity 'SUCCESS' named entity 'CLINICAL' named entity 'BETTER' named entity 'INFECTION' named entity 'DESIGN' named entity 'VIRUS' named entity 'HIV-1 INFECTION' named entity 'HUMAN IMMUNODEFICIENCY VIRUS TYPE 1' named entity 'FAILED' named entity 'APPROACHES' named entity 'CHARACTERIZATION' named entity 'INFECTIONS' named entity 'ESCAPE' named entity 'MECHANISMS' named entity 'ENV' named entity 'VIRUSES' named entity 'ANTIBODY' named entity 'VACCINES' named entity 'BASED' named entity 'VACCINE CANDIDATE' named entity 'BIOLOGICAL PROPERTIES' named entity 'CLINICAL TRIALS' named entity 'HERE' named entity 'DETAILED' named entity 'TO REDUCE' named entity 'PATIENT' named entity 'DUE TO' named entity 'SUBSET' named entity 'FAR' named entity 'ENV' named entity 'THE HARD' named entity 'WAY' named entity 'ANTIBODY' named entity 'ACCOUNT' named entity 'VECTOR' named entity 'ENVELOPE' named entity 'MULTIPLE' named entity 'VIREMIA' named entity 'BASED' named entity 'BROADLY NEUTRALIZING ANTIBODIES' named entity 'ANTI-RETROVIRAL THERAPY' named entity 'IMMUNOGENS' named entity 'EPITOPES' named entity 'NUMBER OF' named entity 'CHRONIC DISEASE' named entity 'VACCINE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software